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opIntroduction: There is increasing concern regarding the ﬁnancial burden of cancer on patients and
their families. This study presents nationally representative estimates of annual out-of-pocket
(OOP) burden among non-elderly cancer survivors and assesses the association between high OOP
burden and access to care and preventive service utilization.
Methods: Using the 2008–2012 Medical Expenditure Panel Survey, 4,271 cancer survivors and
96,780 individuals without a history of cancer were identiﬁed, all aged 18–64 years. High annual
OOP burden was deﬁned as spending 420% of annual family income on OOP healthcare costs.
Associations between high OOP burden and access to care were evaluated with multivariable logistic
regression. Analyses were conducted in 2015.
Results: Compared with individuals without a cancer history, cancer survivors were more likely to
report a high OOP burden (4.3% vs 3.4%, p¼0.009) in adjusted analyses. High OOP burden was
more common among cancer survivors who were poor (18.4%), with either public insurance (7.9%)
or uninsured (5.7%), and not working (10.2%). Among cancer survivors, high OOP burden was
associated with being unable to obtain necessary medical care (19.2% vs 12.5%, p¼0.002), delaying
necessary medical care (21.6% vs 13.8%, p¼0.002), and lower breast cancer screening rates among
age-appropriate women (63.2% vs 75.9%, p¼0.02).
Conclusions: High OOP burden is more common among adults with a cancer history than those
without a cancer history. High OOP burden was associated with being unable to obtain necessary
medical care, delaying necessary medical care, and lower breast cancer screening rates
among women.
(Am J Prev Med 2015;49(6S5):S489–S497) Published by Elsevier Inc. on behalf of American Journal of
Preventive Medicine. This is an open access article under the CC BY-NC-ND license
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en access article under the CC BY-NC-ND license (http:IntroductionAn estimated 14.5 million Americans with ahistory of cancer were alive in 2014.1 Previousresearch has shown that cancer survivors face
greater healthcare expenditures including out-of-pocket
(OOP) costs compared with individuals without a history
of cancer.2–5 High OOP costs can reduce access to care,
inﬂuence clinical practice, and affect treatment choices.6,7
By creating a ﬁnancial barrier, OOP payments can lead to
reduced use of preventive services and uptake of pre-
ventive medications.6,8 For example, higher OOP costs
are associated with lower rates of screening for breast
cancer, cervical cancer, and colorectal cancer among
certain populations.8–10 Reduced access to care amonge Medicine.
//creativecommons.org/licenses/by-nc-nd/4.0/).
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for disease recurrence, screening for additional cancers,
and care for the late and lasting effects of cancer
treatment.11,12
Limited information exists on OOP burden among
cancer survivors at the national level. Previous studies
have addressed OOP burden among cancer survivors by
treatment status, rather than among all cancer survivors
together,5,13 or have focused on cancer patients aged
Z65 years.13 Additionally, few studies have evaluated the
association between OOP burden and access to care and
preventive service utilization among cancer survivors.
This study provides a comprehensive analysis of OOP
burden among non-elderly adult cancer survivors aged
18–64 years. Using nationally representative data, this
study examines the prevalence of high annual OOP
burden and the association between high annual OOP
burden and access to care and preventive service utiliza-
tion among non-elderly cancer survivors.
Methods
Data Sources
The study sample was selected from the 2008–2012 Medical Expendi-
ture Panel Survey (MEPS) Household Component. The MEPS is a
nationally representative sample of the U.S. civilian non-
institutionalized population that collects detailed information on
demographic characteristics, health status, income, health insurance,
employment, access to care, and healthcare expenditures (including
OOP expenditures). In-person interviews are conducted with an
individual who responds for all members of the household. The annual
response rate ranged from 53.5% to 59.3% during the study years
included in the analysis. More-detailed information on the MEPS
survey design and content is available elsewhere.14,15
Cancer survivors were deﬁned as any person who has ever been
diagnosed with cancer. Using the 2008–2012 MEPS, 4,271 cancer
survivors aged 18–64 years were identiﬁed based on the question:
Has a doctor or other health provider ever told you that you have a
cancer or malignancy of any kind? The comparison group
consisted of the remaining 96,780 adults in the same age range
who did not report a history of cancer. Similar to previous studies,
individuals diagnosed solely with non-melanoma skin cancer were
not classiﬁed as cancer survivors.2,16
Measures
Sociodemographic characteristics of cancer survivors at the time of
the survey included: time since diagnosis, age, sex, race/ethnicity,
educational attainment, marital status, number of comorbid
conditions, health status, health insurance status, employment
status, and family income as a percentage of the federal poverty
level (FPL). Poor people were deﬁned as having family income
o100% FPL, near-poor and low-income people were deﬁned as
having income 100%–200% FPL, and middle- and high-income
people were deﬁned as having incomes Z200% of FPL. The
number of comorbid conditions was determined through a series
of questions about whether a doctor or other healthcareprofessional ever told the person that they had any MEPS priority
condition, including arthritis, asthma, diabetes, emphysema, heart
disease, hypertension, stroke, and high cholesterol.
Annual OOP burden was measured as the percentage of OOP costs
relative to family income. Annual OOP burden included OOP
expenditures toward any healthcare service, such as coinsurance,
copayments, and deductibles. Expenditures include those for cancer
screening, surveillance, and treatment, as well as medical care for other
health conditions. Consistent with previous research, OOP burden was
deﬁned at the family level, as families typically share ﬁnancial
resources.5 Family-level burdens were assigned to individuals within
the family, allowing the analysis to be conducted at the individual level.
Similar to previous studies, high OOP burden was deﬁned as having
annual OOP spending 420% of annual income.5,17 For families
reporting very low or negative incomes (1.8% of cancer survivors in the
sample), a $100 ﬂoor for family income was imposed.5 The results were
not sensitive to the adjustment.
Several access to care measures were evaluated based on both
the availability of care and actual utilization of healthcare services
in the past year. Access to care measures included: having a usual source of care;
 having difﬁculty getting to a usual source of care;
 being unable to get necessary medical care, dental care, or
prescription medications; and
 delaying necessary medical care, dental care, or use of
prescription medications.
Preventive care was evaluated by examining preventive service
use and cancer screening services recommended by the U.S.
Preventive Services Task Force18 and vaccinations recommended
by the Advisory Committee on Immunization Practices19 and
potentially covered by provisions of the Affordable Care Act
(ACA). Preventive services included: blood pressure screening within the past 2 years;
 cholesterol screening within the past 2 years;
 inﬂuenza vaccination in the past year; and
 breast, cervical, and colorectal cancer screening within recom-
mended screening guidelines.
Cancer screening was assessed among age- and gender-eligible men
and women. Receipt of mammography within the past 2 years among
women agedZ40 years was used to identify women up to date with
breast cancer screening guidelines. Receipt of the Pap test within the
past 3 years among women aged 21–64 years who had not had their
cervix removed was used to identify women up to date with cervical
cancer screening guidelines. Adherence to colorectal cancer screening
guidelines was assessed by examining the receipt of a fecal occult blood
test within 1 year, sigmoidoscopy within the last 5 years, or colono-
scopy within the last 10 years among men and women aged 50–64
years to identify individuals up to date with screening. Individuals with
a history of the speciﬁc cancer in each analysis were excluded to ensure
that preventive screenings were captured rather than surveillance.20
Statistical Analysis
Descriptive statistics were calculated for cancer survivors and
individuals without a history of cancer and compared using chi-
square statistics. Multivariable logistic regression models control-
ling for age, sex, race/ethnicity, marital status, education, andwww.ajpmonline.org
Guy Jr et al / Am J Prev Med 2015;49(6S5):S489–S497 S491number of comorbidities were used to compare annual OOP
burden among cancer survivors and individuals without a history
of cancer. Overall results and results stratiﬁed by demographic
factors as well as family income, health insurance, and employ-
ment status are presented. The adjusted percentages of adults with
a high OOP burden are presented as predictive margins, which
standardize the outcome of each group to the covariate distribu-
tion of the population.21
Multivariable logistic regression models were used to assess the
relationship between high OOP burden and access to care and
preventive service utilization among cancer survivors. Predictive
margins were generated to compare these measures among cancer
survivors by OOP burden status controlling for age, sex, race/
ethnicity, marital status, education, and number of comorbidities.
Person-level weights were applied to account for the complex
study design of the MEPS and reﬂected probability of selection,
adjustments for non-response, and post-stratiﬁcation to provide
nationally representative estimates. All analyses were conducted
using Stata, version 14.0. Analyses were conducted in 2015.Results
Cancer survivors were more likely to be older, female,
non-Hispanic white, have more comorbid conditions,
report being in fair or poor health, insured, more likely to
be married, and more likely not to be working than
individuals without a history of cancer (Table 1). More
than a third of cancer survivors (36.7%) were diagnosed
within the past 4 years, and 39.1% were diagnosed at least
10 years before the survey.
Cancer survivors were more likely to have a high annual
OOP burden compared with those without a history of
cancer. After adjusting for other covariates, 4.3% of cancer
survivors had a high OOP burden compared with 3.4% of
individuals without a history of cancer (p¼0.009, Table 2).
Among individuals aged 50–64 years, cancer survivors
were more likely to report a high total OOP burden than
individuals without a history of cancer (p¼0.02), whereas
similar rates of high OOP burden were found among those
aged 18–49 years regardless of their cancer history. Near-
poor and low-income along with middle- and high-
income cancer survivors were more likely to have a high
annual OOP burden compared with individuals in the
same poverty level categories but without a history of
cancer (p¼0.02 and p¼0.003, respectively). High OOP
burden was more common among privately insured
cancer survivors than among privately insured individuals
without a history of cancer (po0.001). High OOP burden
was more common among cancer survivors working full-
time than among individuals without a history of cancer
working full-time (p¼0.02).
Among cancer survivors, the prevalence of high
annual OOP burden varied across a number of socio-
demographic characteristics. High OOP burden was
more common among the poor (18.4%) and the near-December 2015poor and low-income (4.6%), compared with those with
middle and high incomes (1.0%). Among cancer survi-
vors, high OOP burden was more common among those
with public insurance (7.9%) and the uninsured (5.7%)
compared with cancer survivors with private health
insurance (3.2%). High OOP burden was more common
among cancer survivors who were not working (10.2%)
compared with those working part-time (4.2%) and those
working full-time (1.7%).
Cancer survivors with a high annual OOP burden were
more likely to report that they were unable to obtain
necessary medical care, dental care, or prescription
medications (19.2% vs 12.5%, p¼0.002) and delayed
necessary care (21.6% vs 13.8%, p¼0.002) compared
with cancer survivors without a high OOP burden
(Table 3). Among female cancer survivors, breast cancer
screening rates were lower among those with a high OOP
burden compared with those without a high OOP burden
(63.2% vs 75.9%, p¼0.02).
Discussion
This study demonstrates that cancer survivors are more
likely to report a high annual OOP burden than
individuals without a history of cancer. High annual
OOP burden is more common among poor cancer
survivors, those with public insurance or the uninsured,
and those not working. Among cancer survivors, high
OOP burden is associated with being unable to obtain
necessary medical care and delaying necessary medical
care. Additionally, high OOP burden is associated with
lower breast cancer screening among age-appropriate
female cancer survivors.
Although there is literature underscoring the ﬁnancial
burden of cancer survivorship, this is the ﬁrst study to
quantify the prevalence of high annual OOP burden and its
association with access to health care and preventive service
utilization among non-elderly cancer survivors at the
national level. These ﬁndings support previous research
among cancer survivors highlighting the association between
higher cost sharing requirements and forgoing or delaying
medical care.22,23 Access to care is particularly important for
cancer survivors, given their increased risk of developing
other chronic conditions, and long-term adverse health
effects, including cardiotoxicity, lymphedema, sexual dys-
function, incontinence, pain, fatigue, cognitive dysfunction,
and psychological distress.24,25 Cancer survivors also have an
increased risk of secondary cancers.26,27 Previous studies have
highlighted disparities in access to care among cancer
survivors and the importance of ongoing efforts to improve
access to care among this population.20
The ﬁndings suggest that non-elderly female cancer
survivors who reported a high annual OOP burden were
Table 1. Characteristics of Nonelderly Cancer Survivors and Individuals Without a History of Cancer: Medical Expenditure
Panel Survey, 2008-2012
Characteristics
Cancer survivors,
% (95% CI)
(n=4,271)
Individuals without a history of cancer,
% (95% CI)
(n=96,780) p-value
Time since diagnosis (years)
0–4 36.7 (34.3–39.1) —
5–9 22.4 (20.8–24.2) —
10–19 23.8 (21.9–25.8) —
Z20 15.3 (13.6–17.1) —
Missing 1.9 (1.3–2.7) —
Age (years) o0.001
18–39 15.1 (13.5–16.9) 48.9 (48.0–49.7)
40–49 20.0 (18.2–21.8) 21.7 (21.2–22.3)
50–64 64.9 (62.5–67.3) 29.4 (28.6–30.3)
Sex o0.001
Men 35.0 (32.7–37.3) 50.1 (49.7–50.5)
Women 65.0 (62.7–67.3) 49.9 (49.5–50.3)
Race/ethnicity o0.001
Non-Hispanic white 81.3 (79.2–83.1) 63.9 (62.0–65.8)
Non-Hispanic black 7.9 (6.7–9.2) 12.3 (11.1–13.7)
Hispanic 7.3 (6.2–8.6) 16.2 (14.6–18.0)
Non-Hispanic other 3.6 (2.7–4.8) 7.5 (6.6–8.5)
Education o0.001
Less than high school graduate 11.7 (10.4–13.2) 15.5 (14.8–16.2)
High school graduate 27.7 (25.7–29.9) 28.4 (27.6–29.3)
Some college or more 60.4 (58.0–62.9) 55.7 (54.5–56.8)
Marital status o0.001
Married 61.5 (58.7–64.3) 52.2 (51.3–53.1)
Not married 38.5 (35.7–41.3) 47.8 (46.9–48.7)
Number of comorbiditiesa o0.001
None 24.7 (22.5–27.0) 51.6 (50.9–52.3)
One 24.8 (22.8–27.0) 23.9 (23.4–24.3)
Two 21.1 (19.1–23.2) 12.9 (12.5–13.3)
Three or more 29.4 (27.2–31.7) 11.6 (11.2–12.1)
Health status o0.001
Excellent/Very good 40.8 (38.5–43.0) 62.3 (61.4–63.1)
Good 31.1 (29.3–33.0) 27.1 (26.4–27.7)
Fair/Poor 28.1 (26.2–30.0) 10.7 (10.3–11.1)
(continued on next page)
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Table 1. Characteristics of Nonelderly Cancer Survivors and Individuals Without a History of Cancer: Medical Expenditure
Panel Survey, 2008-2012 (continued)
Characteristics
Cancer survivors,
% (95% CI)
(n=4,271)
Individuals without a history of cancer,
% (95% CI)
(n=96,780) p-value
Health insurance 0.03
Any private 74.4 (72.3–76.5) 70.5 (69.3–71.7)
Public only 14.9 (13.3–16.6) 10.6 (10.0–11.3)
Uninsured 10.7 (9.3–12.2) 18.9 (17.9–19.8)
Employment status o0.001
Full time 51.3 (48.5–54.1) 61.4 (60.7–62.1)
Part time 16.5 (14.8–18.2) 18.9 (18.4–19.4)
Not working 32.2 (30.0–34.6) 19.7 (19.1–20.3)
Family income o0.001
Poor (o100% FPL) 12.8 (11.6–14.1) 13.1 (12.4–13.8)
Near poor and low income
(100%–200% FPL)
14.6 (13.2–16.1) 16.5 (15.9–17.1)
Middle and high income (4200% FPL) 72.5 (70.5–74.4) 70.2 (69.2–71.3)
OOP healthcare expenditures ($)b 2,171 (1,970–2,373) 1,409 (1,360–1,459) o0.001
Note: Boldface indicates statistical signiﬁcance (po0.05). Sample sizes are unweighted.
aComorbidities include arthritis, asthma, diabetes, emphysema, heart disease, hypertension, stroke, and high cholesterol.
bOOP health care expenditures are in 2012 U.S. dollars.
FPL, federal poverty level; OOP, out-of-pocket.
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to recommended preventive care such as breast cancer
screening is critical for cancer survivors, as they are at an
increased risk of developing other cancers and may
experience late and lasting effects of cancer treat-
ment.25–27 The ACA provides many opportunities for
prevention. Millions of Americans are now eligible for
health insurance coverage through the Health Insurance
Marketplace and Medicaid expansion in most states,
giving them better access to health services, including
preventive services. The ACA requires non-
grandfathered private health plans and newly eligible
beneﬁciaries of the Medicaid expansion to provide
coverage without cost sharing for preventive services
rated as “A” (strongly recommended) or “B” (recom-
mended) by the U.S. Preventive Services Task Force, for
vaccinations recommended by the Advisory Committee
on Immunization Practices, and services for infants,
women, and children recognized by the Health Resources
and Services Administration.28 By requiring many plans
to cover recommended clinical preventive services with
no cost sharing to the patient, including screening for
breast, cervical, and colorectal cancer, the ACA can helpDecember 2015reduce ﬁnancial barriers to the receipt of recommended
preventive care. However, it is not clear if these changes
alone will increase access to care among cancer survivors
faced with high annual OOP burden. Other barriers such
as lack of paid sick leave may inhibit the receipt of
recommended preventive services.29 Ongoing evaluation
of access to recommended preventive care will be
important as the ACA continues to be implemented.30
The current study found that high annual OOP
burden is associated with higher rates of delaying or
forgoing needed medical care among cancer survivors.
Delaying or forgoing needed medical care among cancer
survivors may negatively affect surveillance for disease
recurrence and care for the late and lasting effects of
cancer treatment.11,12 Higher OOP costs have also been
shown to reduce adherence to cancer treatment.23,31 In a
survey of medical oncologists, 84% reported that patient
OOP spending inﬂuenced treatment recommendations,7
with 16% acknowledging that they omitted treatment
options on the basis of their perceptions of patients’
ability to afford treatment.32 The American Society of
Clinical Oncology Value in Cancer Care Task Force has
emphasized the important role of patient and provider
Table 2. Prevalence of High OOP Burdena Among Nonelderly Cancer Survivors and Individuals Without a History of Cancer:
Medical Expenditure Panel Survey, 2008–2012
Characteristics
Cancer survivors,
% (95% CI)b
(n=4,271)
Individuals without a history of cancer,
% (95% CI)b
(n=96,780) p-value
Total 4.3 (3.5–5.0) 3.4 (3.2–3.6) 0.009
Age (years)
18–39 3.8 (2.3–5.3) 2.8 (2.6–3.0) 0.13
40–49 3.4 (2.1–4.6) 3.2 (2.9–3.6) 0.81
50–64 5.7c (4.4–6.9) 4.3 (3.8–4.7) 0.02
Sex
Men 4.1 (2.9–5.3) 2.9 (2.8–3.1) 0.04
Women 4.6 (3.8–5.5) 3.8 (3.5–4.0) 0.04
Race/ethnicity
Non-Hispanic white 4.2 (3.3–5.0) 3.4 (3.1–3.6) 0.046
Non-Hispanic black 5.3 (3.5–7.1) 4.0 (3.6–4.4) 0.13
Hispanic 4.3 (2.6–5.9) 3.0 (2.7–3.4) 0.11
Non-Hispanic other 3.8 (1.1–6.5) 3.2 (2.6–3.8) 0.60
Family income
Poor (o100% FPL) 18.4d (15.1–21.7) 19.3 (18.2–20.3) 0.63
Near poor and low income
(100%–200% FPL)
4.6d (3.2–6.1) 3.2 (2.7–3.6) 0.02
Middle and high income (4200% FPL) 1.0 (0.5–1.5) 0.5 (0.4–0.6) 0.003
Health insurance
Any private 3.2 (2.4–4.0) 1.9 (1.7–2.1) o0.001
Public only 7.9 (5.9–9.8) 8.5 (7.8–9.2) 0.55
Uninsured 5.7 (4.1–7.3) 6.1 (5.6–6.6) 0.63
Employment status
Full time 1.7 (1.1–2.2) 1.1 (1.0–1.2) 0.02
Part time 4.2 (2.5–6.0) 3.1 (2.8–3.5) 0.19
Not working 10.2e (8.4–12.1) 10.5 (9.8–11.2) 0.77
Note: Boldface indicates statistical signiﬁcance (po0.05).
aHigh OOP burden was deﬁned as having annual out-of-pocket expenditures on healthcare services in excess of 20% of annual family income.
bPredicted marginals from a logistic regression model controlling for age, sex, race/ethnicity, marital status, education, and number of comorbidities.
cHigh OOP burden was higher among cancer survivors age 50–64 years than among cancer survivors age 18–39 years (po0.05).
dHigh OOP burden was higher among poor and near poor and low-income cancer survivors than among middle and high-income cancer survivors
(po0.05).
eHigh OOP burden was higher among not working cancer survivors than among cancer survivors working full time and part time (po0.05).
FPL, federal poverty level; OOP, out-of-pocket.
Guy Jr et al / Am J Prev Med 2015;49(6S5):S489–S497S494communication on issues surrounding cost.33 However,
many physicians may be uncomfortable discussing costs
with patients.32 The negative impact on the health of
cancer patients because of high OOP costs and the
ﬁnancial burden associated with treatment related to
cancer has been characterized by Ubel and colleagues34 as“ﬁnancial toxicity.” As these authors have explained,
providers frequently discuss toxicities of treatment, but
these discussions typically refer to the physical side
effects of treatment. Meanwhile, ﬁnancial toxicities can
also have a substantial impact on the quality of life of
patients and their families. Patients may be faced withwww.ajpmonline.org
Table 3. Access to Care and Preventive Service Utilization Among Nonelderly Cancer Survivors by OOP Burden: Medical
Expenditure Panel Survey, 2008–2012
Higha Not high
n % (95% CI)b n % (95% CI)b p-value
Access to care
Has a usual source of care 272 83.3 (77.9–88.6) 3,999 86.7 (85.2–88.1) 0.18
Difﬁcult to get to usual healthcare provider (somewhat or
very difﬁcult) among those with usual source of care
272 9.2 (4.8–13.6) 3,999 6.3 (5.3–7.3) 0.15
Unable to get necessary medical care, dental care, or
prescription medication
272 19.2 (14.5–24.0) 3,999 12.5 (11.2–13.7) 0.002
Delayed any necessary medical care, dental care, or
prescription medication
272 21.6 (16.3–26.9) 3,999 13.8 (12.4–15.2) 0.002
Preventive services
Blood pressure checked in last 2 years 272 96.9 (94.3–99.4) 3,999 97.6 (97.0–98.2) 0.52
Cholesterol checked in last 2 years 272 88.2 (83.6–92.7) 3,999 86.0 (84.6–87.4) 0.38
Inﬂuenza vaccination in the last year 272 45.1 (37.8–52.3) 3,999 49.2 (47.1–51.3) 0.27
Cancer screening (among age- and gender-eligible individuals without the speciﬁc cancer)
Breast cancer screening (mammogram within 2 years)
among women aged Z40 years)
116 63.2 (52.2–74.3) 1,512 75.9 (73.0–78.9) 0.02
Cervical cancer screening (Pap test within 3 years) among
women aged 21–65 years who have not had cervix removed
91 88.9 (81.9–95.9) 1,386 89.8 (87.6–92.0) 0.80
Colorectal cancer screening (FOBT within 1 year,
sigmoidoscopy within 5 years, or colonoscopy within 10
years) among adults aged 50–75 years
169 51.1 (42.0–60.1) 2,306 56.1 (53.4–58.9) 0.28
Note: Boldface indicates statistical signiﬁcance (po0.05).
aHigh OOP burden was deﬁned as having annual out-of-pocket expenditures on health care services in excess of 20% of annual family income.
bPredicted marginals from a logistic regression model controlling for age, sex, race/ethnicity, marital status, education, and number of comorbidities.
FOBT, fecal occult blood test; OOP, out-of-pocket.
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paying for daily living expenses.34 Previous research has
shown that cancer patients were more likely to ﬁle
bankruptcy than individuals without a history of cancer,
with the risk of bankruptcy two to ﬁve times higher
among non-elderly patients given greater variations in
employment, income, insurance status, and personal
assets.35 Open dialogue between providers and their
patients about these issues could help enable informed
decision making that carefully considers both expected
beneﬁts and potential high OOP costs of treatments.35
Limitations
Although the MEPS is one of the most detailed nationally
representative data sources available to estimate OOP
burden among cancer survivors and individuals without
a cancer history, there are a number of limitations in this
study. First, this study relied on household-reported data,
which introduces potential reporting biases. For example,
the cancer diagnosis question in the MEPS refers to
cancer or a malignancy of any kind, which may result inDecember 2015identifying those with pre-invasive disease as cancer
survivors. To the extent that this is the case, the impact
of cancer survivorship on OOP burden would be under-
estimated. Second, this study used family pre-tax income
rather than post-tax income to compute OOP burden.
Although post-tax income may be a more accurate
measure of ﬁnancial resources available to a family,
previous research using the MEPS found that OOP
burden prevalence was very similar when using pre-tax
income, and variations in sociodemographic character-
istics were virtually identical.36 Lastly, the results only
apply to the non-institutionalized civilian adult
population.
Conclusions
High annual OOP burden is more common among
cancer survivors than individuals without a cancer
history. High OOP burden has the potential to reduce
access to care and the utilization of preventive services.
With the continuing increase in the number of cancer
survivors and rising healthcare costs, trends in OOP
Guy Jr et al / Am J Prev Med 2015;49(6S5):S489–S497S496burden among cancer survivors and efforts to improve
communication between patients and providers about
cost will be important to monitor and follow.Publication of this article was supported by the Centers for
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